Early Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For people with Acute Myeloid Leukemia (AML):

• A diagnosis of AML that has been confirmed through laboratory tissue testing, and the cancer cells carry a specific protein called CD70
• The AML has come back or stopped responding to treatment, meaning either: standard chemotherapy did not achieve remission; remission was achieved but lasted less than 12 months; one or more follow-up treatments did not work; or the cancer has relapsed two or more times
• Bone marrow test results show a certain level of abnormal (blast) cells above set thresholds (confirm with trial site for exact values)
• Liver and kidney function blood test results that fall within acceptable ranges set by the trial
• A heart scan (echocardiogram) showing the heart is pumping at 50% or more of its normal capacity
• No active lung infection, and blood oxygen levels at or above 92% while breathing normal indoor air
• A life expectancy estimated at 3 months or more
• A general health and activity level score of 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities)
• Willingness to take part and ability to sign a consent form (a legal guardian may sign on behalf of the patient if needed)

For people with Non-Hodgkin Lymphoma (NHL):

• People of any gender and age may be considered
• A confirmed diagnosis of one of the following specific types of lymphoma, identified through laboratory tissue testing: DLBCL (NOS), Follicular Lymphoma, DLBCL transformed from CLL/SLL, Primary Mediastinal B-Cell Lymphoma, or High-Grade B-Cell Lymphoma, and the cancer cells carry the CD70 protein
• The lymphoma has come back or stopped responding to treatment, meaning either: no response or relapse after at least two lines of chemotherapy; the cancer showed resistance to treatment from the start; or relapse occurred after a stem cell transplant using the patient's own cells
• At least one measurable area of disease visible on scans, assessed using a standard set of lymphoma measurement guidelines

For people with Multiple Myeloma (MM):

• A confirmed diagnosis of multiple myeloma that carries the CD70 protein, and the disease meets one of the following: it has returned or stopped responding to treatment according to international myeloma guidelines; there are detectable traces of disease remaining after treatment; or there is disease outside the bone marrow that has been difficult to clear with chemotherapy or radiation
• People of any gender and age may be considered
• Liver and kidney function blood test results that fall within acceptable ranges set by the trial
• A heart scan (echocardiogram) showing the heart is pumping at 50% or more of its normal capacity
• No active lung infection, and blood oxygen levels at or above 92% while breathing normal indoor air
• A life expectancy estimated at 3 months or more
• A general health and activity level score of 0, 1, or 2 on a standard medical scale
• Willingness to take part and ability to sign a consent form (a legal guardian may sign on behalf of the patient if needed)

Who may not be able to join:

• People with a history of serious brain or nervous system conditions, including head injury, loss of consciousness, epilepsy, stroke, or bleeding in the brain
• People with a history of a prolonged QT interval on a heart tracing (ECG), or other serious heart rhythm problems
• People who are pregnant or breastfeeding
• People with a severe active infection (minor infections such as a urinary tract infection or throat infection caused by bacteria may not automatically disqualify someone — confirm with trial site)
• People with an active hepatitis B or hepatitis C infection
• People who have been taking steroid tablets or injections throughout the body within the 2 weeks before screening, unless the steroids are inhaled (such as for asthma)
• People who have previously received any CAR-T cell therapy or other gene-modified T cell treatments
• People whose liver or kidney function blood test results fall outside acceptable limits set by the trial
• People with other serious uncontrolled health conditions that the trial team considers unsuitable (confirm with trial site)
• People living with HIV
• Any other situation that the trial investigators believe could put the patient at increased risk or affect the reliability of the trial results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.